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We studied 11 new kindreds with primary pigmented nodular adrenocortical disease (PPNAD) or Carney complex
(CNC) and found that 82% of the kindreds had PRKAR1A gene defects (including seven novel inactivating mu-
tations), most of which led to nonsense mRNA and, thus, were not expressed in patients’ cells. However, a previously
undescribed base substitution in intron 6 (exon 6 IVS +1GrT) led to exon 6 skipping and an expressed shorter
PRKAR1A protein. The mutant protein was present in patients’ leukocytes and tumors, and in vitro studies indicated
that the mutant PRKAR1A activated cAMP-dependent protein kinase A (PKA) signaling at the nuclear level. This
is the first demonstration of an inactivating PRKAR1A mutation being expressed at the protein level and leading
to stimulation of the PKA pathway in CNC patients. Along with the lack of allelic loss at the PRKAR1A locus in
most of the tumors from this kindred, these data suggest that alteration of PRKAR1A function (not only its complete
loss) is sufficient for augmenting PKA activity leading to tumorigenesis in tissues affected by CNC.
Carney complex (CNC [MIM 160980]) is a familial
multiple neoplasia syndrome transmitted as an autoso-
mal dominant trait (Carney et al. 1986). CNC was in-
itially described as the association of myxomas, spotty
skin pigmentation, and endocrine overactivity (Carney
et al. 1985). A variety of endocrine and nonendocrine
tumors occur in patients with CNC (Carney 1990; Car-
ney and Toorkey 1991; Carney and Stratakis 1996,
1998; Premkumar et al. 1997; Stratakis et al. 1997; Pack
et al. 2000; Raff et al. 2000; Stratakis et al. 2000; Carney
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et al. 2001). Primary pigmented nodular adrenocortical
disease (PPNAD), a rare cause of ACTH-independent
Cushing syndrome, is the main endocrine manifestation
of CNC. PPNAD is observed in one-fourth of patients
with CNC (Stratakis et al. 1999, 2001).
Approximately half of the cases of CNC are familial
(Stratakis et al. 2001). Putative genetic loci have been
identified by linkage analysis at chromosome 2p16 and
17q22-24 (Stratakis et al. 1996; Casey et al. 1998). Re-
cently, the responsible gene on 17q22-24, PRKAR1A,
was identified (Kirschner et al. 2000a); additional mu-
tations in this gene were described later in other kindreds
(Casey et al. 2000; Kirschner et al. 2000b). PRKAR1A
encodes the type 1a regulatory subunit of cAMP-de-
pendent protein kinase A (PKA). Overall, inactivating
mutations of this gene have been observed in ∼41% of
CNC kindreds (Kirschner et al. 2000b).
All of the PRKAR1A defects reported so far are func-
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Table 1
Clinical Manifestations among the Index Cases
Family Lentigines
Heart
Myxoma PPNAD Endocrine Manifestations Other
CNC07  
CNC03  
CNC09   GH-PRL pituitary-producing adenoma Ethmoidal osteochondromyxoma;
PMS; blue nevus; breast ductal
adenoma
CNC04    Toxic multinodular goiter; ovarian cyst Benign hepatoma; PMS; breast ductal
adenoma; splenic lipoma; skin myx-
oma; mesenteric myxoma; pelvic
leiomyoma; pancreatic acinar
adenocarcinoma
CNC08  Ovarian cyst Blue nevus
CNC06   
CNC02   Calcifications on testicular ultrasonography Blue nevus
CNC01    Thyroid tumor Acromegaly Benign hepatoma
CNC05  
CNC10  
CNC11  Ovarian cyst PMS; breast ductal adenoma
NOTE.—Abbreviations: ; hormone; ; melanotic schwannoma.p present GHp growth PRLp prolactin PMSp psammomatous
Table 2
Novel PRKAR1A Oligonucleotide Sequences for Mutation
Detection

























tionally null mutations. All sequence changes were pre-
dicted to cause premature stop codons, with the excep-
tion of one mutation that altered the transcriptional start
site (at the ATG codon) (Kirschner et al. 2000b). It was
then demonstrated that mutant mRNAs bearing a pre-
mature stop codon were unstable, as a result of non-
sense-mediated mRNA decay (NMD) (Kirschner et al.
2000b). It is interesting that PRKAR1A seems to func-
tion as a classic tumor-suppressor gene in tumors from
CNC patients as demonstrated by loss of the normal
allele in CNC lesions (Kirschner et al. 2000a). Loss of
the normal PRKAR1A protein and NMD of the mutant
allele in these studies suggested that oncogenesis in CNC
tumors was due to the complete absence of a functional
PRKAR1A.
In the present study, 11 kindreds with CNC, in which
almost all index cases were referred for Cushing syndrome
caused by PPNAD, were investigated for PRKAR1A
germline mutations. Family members were evaluated by
a thorough history and physical exam. Affection status
was determined on the basis of the diagnostic criteria
proposed recently (Stratakis et al. 2001) and as reported
by Groussin et al. (2002). Clinical data of all the index
cases are shown in table 1.
DNA was extracted as reported elsewhere (Groussin
et al. 2002), and the 12 exons and the flanking intronic
sequences of the PRKAR1A gene were separately PCR
amplified using the primers and the conditions described
elsewhere for exons 1A, 1B, 2, and 7 (Kirschner et al.
2000b) and the oligonucleotides listed in table 2 for
exons 3, 4A, 4B, 5, 6, 8, 9, and 10. Sequencing was
performed as reported elsewhere (Groussin et al. 2002).
Ethnically matched controls ( ) and the CEPHNp 90
collection of DNA samples ( ) were tested forNp 100
PRKAR1A pathogenic disease-causing mutations; none
was found, although some of the common polymor-
phisms of this gene were present (data not shown).
To prepare total cellular protein extracts, cultured
lymphocytes were harvested and pelleted. Tumor tissues
were obtained as reported elsewhere (Groussin et al.
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Table 3
PRKAR1A Mutations in Nine Families with CNC
Family Mutation Effect on RIa
CNC07 Exon 1B 12GrA Additional out-of-frame ATG initiation codon within a consensus sequence for translation
initiation; could abolish translation of the wild-type protein
CNC03 Exon 4B IVS 1GrA Exon skipping
CNC09 Exon 4B 578 delTG Frameshift after codon 163; stop codon after 4 missense residues
CNC04 Exon 6 IVS 1GrT Exon skipping
CNC08 Exon 7 IVS del (7r2) Exon skipping
CNC06 810 ins A (exon 7) Frameshift after codon 241; stop codon after 6 missense residues
CNC02 815 del 13 bp (exon 7) Frameshift after codon 243; stop codon after 9 missense residues
CNC01 850 del AT (exon 7) Frameshift after codon 255; stop codon after 13 missense residues
CNC05 Exon 8 IVS 3ArG Activation of a cryptic splice site
2000). Protein assays were performed using the protein
assay kit (Bio-Rad Laboratories). Equivalent protein
concentrations were resolved by electrophoresis on 10%
SDS-polyacrylamide gel and were transferred to nitro-
cellulose sheets. Western blotting was performed with
primary mouse antibody to the RIa subunit (1/250; Bec-
ton Dickinson Transduction Laboratories). For detection
of the first antibody with a goat anti-mouse IgG antibody
(1/5000; Santa Cruz; sc-2005), chemiluminescence was
used.
For loss of heterozygosity (LOH) analysis, DNA from
different tumors of the proband from family CNC04 was
analyzed along with a paired DNA sample from periph-
eral blood. Seven microsatellite markers located on
17q22-24 were used: centromere-D17S807, D17S1882,
D17S1813, PRKAR1A(CA)n, D17S795, D17S789, and
D17S840-telomere. The sequences of the primers and ge-
nomic order of their loci were derived from the publicly
available genomic databases (Genome Database; White-
head Institute MIT, Center for Genome Research Web
site). Markers were PCR amplified with end labeled 32P-
radiolabeled oligonucleotide primers, and 30 cycles were
performed (95C for 30 s, 51C for 40 s, 72C for 40 s),
followed by a final 5-min extension at 72C. Aliquots of
amplified DNA were mixed with an equal volume of
loading buffer, were denatured at 94C for 5 min, and
were electrophoresed on a 6% polyacrylamide gel. Gels
were dried and placed on Kodak X-Omat films. Marker
PRKAR1A(CA)n PCR fragments were analyzed by elec-
trophoresis through 4% polyacrylamide gel and were
visualized with ultraviolet light after staining with eth-
idium bromide.
A PCR-cloning method was used to construct both
wild-type and exon 6–skipping mutant expression con-
structs. Total RNA was extracted from peripheral blood
leukocytes of family CNC04 proband using RNABle
(Eurobio). cDNA was synthesized by Moloney murine
leukemia virus-reverse transcriptase (Invitrogen). RIa
cDNA from lymphocytes was amplified using the prim-
ers 5′-GAG CAA AGC GCT GAG GGA GCT C-3′
(sense) and 5′-AAG CAT GGA TTG GGG AGA GGA
G-3′ (antisense). The reaction performed with Expand
Long Template PCR System (Roche) consisted of 2 min
at 94C, followed by 35 cycles of 30 s at 94C, 30 s at
58C, and 2 min at 72C. The PCR fragments corre-
sponding to the full-length wild-type RIa cDNA and the
natural mutant with the exon 6 skipping were electro-
phoresed on agarose gel and were purified by using a
QIA quick gel extraction kit (Qiagen). These were in-
troduced into the pGEM-T easy vector by using a TA
cloning kit (Promega). The two constructs were verified
by sequencing before a second PCR amplification was
performed using Pwo DNA Polymerase (Roche). Each
sample was incubated successively at 94C for 15 s, 63C
for 30 s, 72C for 1 min, for a total of 30 cycles, followed
by a final extension at 72C for 7 min. The following
specific oligonucleotide primers were used: HA-RIa
sense primer containing a HindIII site with the hemag-
glutinin HA sequence (underlined): 5′-CCT CCA AGC
TTG CCA CCA TGG CTT ACC CAT ACG ACG TCC
CAG ACT ACG CTG AGT CTG GCA GTA CCG CCG
CC-3′ or nonHA-RIa sense primer: 5′-CCT CCA AGC
TTG AGA ACC ATG GAG TCT GGC-3′; a common
antisense primer containing a Xho site: 5′-CCG TTC
TCG AGT CAG ACA GAC AGT GAC ACA AAA CT-
3′. The four products were purified by gel electropho-
resis, were digested with HindIII and Xho, and were
cloned into the HindIII/Xho sites of the pREP4 expres-
sion vector (Invitrogen) to create HA-RIa-WT, HA-RIa-
D184–236, RIa-WT, and RIa-D184–236. All constructs
were sequenced prior to their use in expression studies.
Lymphocytic cell culture and cycloheximide treatment
were performed as reported elsewhere (Kirschner et al.
2000b).
COS7 cells were cultured in Dulbecco’s modified Ea-
gle medium supplemented with 10% FCS, glutamine,
and gentamycine. The cells were plated in six-well dishes
and were transfected 24 h later by using Lipofectamine
Plus (Invitrogen) following the protocol provided. We
used the luciferase reporter pSS-CRE-LUC containing a
sequence of the rat somatostatin gene71–53 (including
the CRE site) inserted in the 5′-region of the luciferase
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Figure 1 Pedigrees of seven families with a heterozygous mutation of PRKARIA gene. Half-filled squares and circles represent heterozygous
mutated male and female patients, respectively. Open squares and circles represent unaffected patients. The individuals who were studied in
each generation are numbered. Question marks (?) represent individuals of unknown affection status. The proband is indicated by the arrow.
The results of nondenaturing polyacrylamide gel electrophoretic analysis of mutated exons are shown below the three pedigrees. The presence
of heteroduplexes (upper bands), which are formed by the combination of mismatched alleles, confirms heterozygosity for mutated patients.
Migration of the PCR products of family CNC02 shows abnormal bands only for proband with a heterozygous 13-bp deletion in exon 7. The
upper bands correspond to heteroduplexes, the lower bands to normal and mutant alleles.
gene. The reporter gene RSV-bGal (Bertherat et al. 1995)
was used as an internal control for transfection effi-
ciency. Cells were cotransfected with 0.2 mg of pSS-CRE-
LUC, 0.25 mg of RSV-bGal, and 1.5 mg of plasmid
expressing HA-RIa-WT or molar equivalent of HA-RIa-
D184–236 and empty pREP4 plasmids. Six hours prior
to harvesting, half of the transfected dishes were incu-
bated in a mixture of 105 M forskolin (Sigma) and 0.5
mM 3-isobutyl-1-methylxanthine (Sigma). Cells were
harvested 24 h after transfection and were subjected to
lysis; luciferase activity was then assayed for and was
normalized to b-galactosidase activity. All transfection
experiments were performed in triplicate and were re-
peated five times; the results are expressed as the means.
Statistical significance was assessed by a Student’s t test
(StatView 5.0., SAS Institute). Control immunoblotting
analysis was performed to confirm that HA-RIa con-
structs had equivalent levels of expression. Total lysates
from empty vector, HA-RIa-WT, or HA-RIa-D184–236
COS transfected cells were used in Western blotting,
which then was evaluated by chemiluminescence using
anti-HA antibody (Santa Cruz, sc-805).
Sequencing of the 12 coding exons of the genomic
DNA from the index cases revealed a PRKAR1A mu-
tation in the heterozygotic state in 9 of the 11 kindreds
(details are given in table 3 and figs. 1, 2, and 3). Seven
of these mutations have not been previously reported.
Four of them occurred de novo (fig. 1). The 578 delTG
and the exon 8 IVS  3 ArG mutations were reported
elsewhere (Kirshner et al. 2000b). The 578 delTG mu-
tation is the most frequent CNC mutation found to oc-
cur de novo in more than eight kindreds so far; founder
effect has been excluded in most of these kindreds by
extensive genotyping of chromosome 17 markers when
relatives were available (data not shown).
The mutation found in one kindred (CNC04) was a
GrT transversion in the 5′ splice-donor site of intron 6.
The proband had died of a severe form of CNC; her
severely affected son also had the mutation, but her un-
affected mother did not (fig. 3A). This unique mutation
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Figure 2 A heterozygous GrA transversion in exon 1B gives rise to a novel ATG translation initiation codon. A, Pedigree of family
CNC07. The proband is indicated by the arrow. B, Sequencing of PRKAR1A exon 1B revealed a heterozygous mutation that creates an upstream,
out-of-frame ATG codon in the RIa1B mRNA within a consensus sequence for translation initiation. This AUG codon is classified as a strong
start site on the basis of the A and G, respectively, at position 3 and 4 (Kozak 1997). According to the scanning model of eukaryotic
translation, the novel ATG should initiate translation of a truncated protein and decrease translation from the wild-type start codon (Kozak
1999), as administrated for CDKN2A gene (Liu et al. 1999). The location of mutant ATG codon is shown with a horizontal band. The mutation
is indicated by an arrow.
was predicted to lead to exon skipping; however, the
sequence change was in frame, because exon 6 contains
53 triplet codons, making it unlikely that NMD was
ongoing (fig. 3B). In fact, the mutant mRNA was present
in the proband’s peripheral lymphocytes before and after
treatment with cycloheximide (fig. 3C), consistent with
an exon 6 skipping mutation, exon 6 IVS del(9r2),
shown elsewhere (Kirschner et al. 2000b).
Exon 6 is located in the region encoding for cAMP-
binding domain A and gives rise to 53 amino acids
(184–236) of the human RIa subunit. To detect short-
ened RIa forms (RIa-D184–236), we performed west-
ern-blot analysis of cell lysates from peripheral lympho-
cytes from six CNC patients with known mutations of
the PRKAR1A gene, including the proband of family
CNC04 and three control subjects (fig. 4A). Only the
patient with the exon 6 mRNA skipping mutation
showed the shortened RIa form. We then studied five
different tumors from this patient (adrenal nodules [left
and right PPNAD], a pancreatic adenocarcinoma,
schwannoma, and hepatoma); the deleted form of RIa
was found in all tumors (fig. 4B). It is interesting that
only the pancreatic adenocarcinoma demonstrated loss
of expression of the RIa wild-type protein. To under-
stand the mechanism underlying this observation, we
performed LOH analysis using peripheral blood DNA
and DNA from the tumors examined above. Seven
markers located around the PRKAR1A gene were stud-
ied, including the intragenic dinucleotide repeat. Con-
sistent with the western blotting data, only the malignant
tumor showed LOH for all informative markers, in-
cluding the intragenic one (fig. 4C).
To investigate the consequences of the deleted form
of the RIa protein at the transcriptional level, transient
transfections were performed under the assumption that
changes in expression of cAMP-responsive genes reflect
PKA activity, as shown elsewhere (Gonzalez and Mont-
miny 1989). We created HA-expression vectors for the
wild-type RIa protein (RIa-WT) and the deleted mutant
(RIa-D184–236). Forskolin, an adenylyl-cyclase acti-
vator and IBMX, a phosphodiesterase inhibitor, were
used as stimulants of the cAMP signaling pathway. We
then examined the effects of the wild-type RIa and RIa-
D184–236 on the activity of a luciferase reporter gene
under the control of the somatostatin promoter con-
taining a cAMP-responsive element (CRE), a binding site
for ATF/CREB transcription factors. As shown in figure
5A, RIa-D184–236 showed higher transcriptional activ-
ity of the CRE-somatostatin gene than empty vector or
wild-type RIa transfected cells. This effect was present
at baseline but was augmented after exposure to for-
skolin and IBMX. As shown in figure 5B, this is not
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Figure 3 An exon 6 splice-site mutation leads to an exon 6 skipping in family CNC04. A, Pedigree of family CNC04. The subjects who
were studied in each generation are numbered. The question mark (?) represents an individual of unknown affection status. The proband (II.1)
is indicated by the arrow. She presented with a severe form of Carney complex and died of a pancreatic adenocarcinoma with rapidly growing
liver metastasis. Her unaffected mother was also investigated for the presence of the mutation. Only the proband and her affected son were
heterozygous for the intron 6 splice mutation. The proband’s sequence trace of the sense strand showed a GrT transversion in the splice donor
site of intron 6. B, Migration, on a 1% agarose gel, of RT-PCR products from transformed lymphocytes and PPNAD from family CNC04’s
proband. After gel extraction and purification, RT-PCR products were directly sequenced. Top, Schematic representation of the gene organization
of coding exons giving rise to the mature RIa mRNA. Regions that encode functional domains are denoted. The localization of the primers
used for the RT-PCR is indicated with arrows. Bottom, Schematic representation of exon 6 skipping mRNA. C, RT-PCR products from
transformed lymphocytes from patient carrying the exon 6 IVS del(9r2) mutation. No change is obvious after 4 h of treatment with 100
mg/ml cycloheximide (X) compared to the vehicle (C).
explained by difference of expression between the two
HA-tagged proteins. We obtained similar results with
the non–HA-expression vectors (data not shown).
In the present study of five sporadic and six familial
cases of PPNAD or CNC, we found nine PRKAR1A
mutations. In four kindreds, the mutation was de novo,
as proven by the investigation of parental DNA (fig. 1),
suggesting a high rate of spontaneously occurring mu-
tations in this gene, as suggested by Kirschner et al.
(2000a). With the exception of two mutations, all others
were unique inactivating heterozygous mutations that
are predicted to lead to a premature termination codon.
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Figure 4 Identification of a deleted form of RIa subunit in proband of family CNC04 and absence of LOH except for the pancreatic
adenocarcinoma. A, Western blotting of RIa subunit in 5 mg protein lysates from transformed lymphocytes of Carney complex patients with
mutation in PRKAR1A gene and three control subjects. Only the CNC patient with an exon 6 skipping mRNA presents a shortened form of
the protein. Size markers are indicated at left. B, Western blotting analysis of 20 mg total cellular proteins prepared from lymphocytes and five
different tumors of family CNC04’s proband. Two bands are present in all tissues of the patient except for the pancreatic adenocarcinoma
where the wild-type RIa is lost. In the schwannoma, RIa-D184–236 was present after longer exposure. The human adrenal cell line H295R is
shown as a control for RIa expression. Size markers are indicated at left. C, LOH analysis was performed using DNA samples from peripheral
blood and four tumors from the same patient. Seven markers located around PRKAR1A were used, including PRKAR1A(CA)n which was
located within the 5′ region of the gene. The five informative loci demonstrated LOH only in the tumor DNA of the pancreatic adenocarcinoma
(a finding consistent with Western blotting data).
This is in accordance with the mutations described to
date, which have been demonstrated to be functionally
null. Mutant mRNAs are degraded by NMD, and pre-
dicted truncated RIa forms are not detected (Kirschner
et al. 2000b). Accordingly, we were not able to detect
truncated protein or mutant mRNA from lymphocytes
or tumors from patients harboring any of the novel
PRKAR1A mutations, with one notable exception (see
below).
PRKAR1A gene defects were identified in ∼41% of
52 CNC kindreds (Kirschner et al. 2000b). In this series,
81% (9/11) of our kindreds had mutations. This differ-
ence, albeit not statistically significant, may be real; it
may be attributed to the different population that we
studied, since our referral basis is Cushing syndrome
caused by PPNAD: indeed, 10 of our 11 probands and
15 of 20 patients with a PRKAR1A mutation had
PPNAD. Moreover, most of our patients were adults. It
was reported recently that pediatric patients with
PPNAD represent a different group of CNC patients
(Sandrini et al. 2002). Taken together, these data suggest
that adult CNC patients presenting with PPNAD and
Cushing syndrome are perhaps more likely to have an
inactivating PRKAR1A. This is also supported by the
presence of frequent germline PRKAR1A mutations in
patients with isolated, sporadic PPNAD who do not
have any other signs of CNC (Groussin et al. 2002).
Among the PRKAR1A new mutations described in
this study, two deserve a special note. First, a 5′ UTR
point mutation in exon 1B created an additional out-of-
frame ATG initiation codon within which a strong con-
sensus sequence for translation initiation was found.
This is the first described mutation of exon 1B. A similar
alteration has been reported for the CDKN2A gene in
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Figure 5 Transcriptional activity of the RIa-WT and RIa-D184–236 on the somatostatin CRE promoter stimulated by forskolin. A, COS
cells were transiently cotransfected with a reporter plasmid expressing luciferase under the control of the somatostatin CRE sequence and
equivalent molar quantity of pREP4 expression vectors for HA-RIa-WT and HA-RIa-D184–236. Cells were left untreated or were stimulated
in the presence of forskolin and IBMX. Experiments were repeated five times with triplicate samples. The figure shows the mean of the five
experiments. All error bars represent standard error of the mean; * denotes significance at ; ** denotes significance at . TheP ! .05 P ! .01
stimulation factor is reported to the transcription level observed in the cells without transfected RIa. B, Control immunoblotting analysis of
whole-cell extracts of HA-RIa expression. Anti-HA antibodies were used in Western blotting with total lysates from empty vector, HA-RIa-
WT, or HA-RIa-D184–236 COS transfected cells.
melanoma-prone families (Liu et al. 1999) and for the
POMC gene in severe early-onset obesity, adrenal in-
sufficiency, and red hair pigmentation (Krude et al.
1998). This mutation involved only one of the two dif-
ferent RIa mRNAs originating from the alternative splic-
ing of the two distinct leader exons, 1A and 1B. But it
seems that the RIa 1B mRNA isoform is particularly
important in mediating tissue-specific regulation of RIa
expression (Dahle et al. 2001).
The second novel mutation that is of particular in-
terest is the one that creates an alternatively spliced var-
iant of RIa, RIa D184–236; it is interesting that this
mutation was identified in a kindred with a severe form
of CNC. This is the first example of abnormal RIa sub-
unit mRNA and protein being present in cells from CNC
patients: the exon 6 donor splice-site mutation leads to
an exon 6 skipping that creates an in-frame, shorter
PRKAR1A mRNA that does not undergo NMD. Ac-
cordingly, the predicted truncated PRKAR1A protein
products could be detected in both peripheral lympho-
cytes and tumors from this kindred. The identification
of this mutation allowed us to examine, for the first time
for a CNC-causing mutation, the in vivo effects that a
shorter RIa has on the PKA signaling system.
The R subunits of PKA are modular proteins com-
posed of several distinct, well-defined, and stable do-
mains (fig. 3B) (McKnight et al. 1988). Two tandem
gene-duplicated cAMP-binding domains are present at
the C terminus; each contains ∼120 amino acids. cAMP-
binding domain A interacts directly with the C subunit
and is essential for high-affinity binding to C; two struc-
turally and functionally distinct subsites were charac-
terized, one that binds cAMP and another that binds to
the C subunit (Huang and Taylor 1998). The mutant
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RIa D184–236 has a 53-aa deletion located in the region
of cAMP-binding domain A, which is known to contain
Glu202 (E202) and Arg211 (R211) cAMP-binding sites.
Cotransfection studies using a cell line expressing both
the mutant and the wild-type RIa subunits (to mimic
the in vivo state) showed loss of any inhibitory effects
on CRE-dependent transcription of the somatostatin
promoter when RIa D184–236 was overexpressed. Ac-
cordingly, measurements of nonstimulated and stimu-
lated luciferase activity were significantly higher when
RIa D184–236 was overexpressed. This difference was
likely to be related to increased PKA activity, since CRE-
dependent transcription reflects nuclear translocation of
the catalytic subunit (Gonzalez and Montminy 1989).
The most likely mechanism by which a truncated RIa
could lead to cAMP signaling alterations is a dominant
negative effect on RIa-mediated inhibition of the PKA
catalytic subunit (Ogreid and Taylor 1990).
To date, PRKAR1A is considered a tumor-suppressor
gene because of the constitutional loss of one allele (func-
tionally null germ line mutations) associated with loss
of the normal allele in CNC tumors. We have studied
several different tumors of the patient with the abnormal
subunit RIa D184–236, including an unusual pancreatic
adenocarcinoma (arising from the acinar cells) to which
the patient succumbed after widespread metastasis. It
should be noted that CNC appears to predispose to this
unusual tumor, since two other patients with CNC have
been reported with similar diagnosis and clinical course
(Stratakis et al. 2001). In our study, complete LOH was
detected only in the pancreatic adenocarcinoma, sug-
gesting that loss of the normal allele is not necessary for
abnormal growth and/or proliferation of cells in CNC-
affected tissues, unless these results are confounded by
“contamination” with normal cells. The latter was un-
likely, given the careful dissection of the lesions from
this patient. Thus, we speculate that the dominant neg-
ative effect of RIa D184–236 is responsible for RIa
downregulation in the initial stages of this tumor, where
LOH was not present. Progression of the tumor was,
perhaps, further favored by loss of the normal allele, as
demonstrated by LOH of the malignant components of
the resected lesion.
In conclusion, we described a high frequency of
PRKAR1A gene mutation in 11 CNC kindreds. Analysis
of the phenotypes may suggest that adult patients with
CNC presenting with Cushing syndrome caused by
PPNAD are more likely to have a PRKAR1A gene defect.
Perhaps the most important finding in our study is that
a defective PRKAR1A protein without concurrent loss
of the normal allele can cause CNC and is associated
with in vitro evidence of increased PKA activity. The
dominant effect of this unique mutant suggests that per-
turbations of PKA may be enough to cause pathology
in CNC-affected cells and has wide implications for the
understanding of the cAMP signaling in tumorigenesis.
Acknowledgments
We thank F. Rene´-Corail, for excellent technical assistance;
the staff of the Banque de Cellules (Prof. M Delpech, CHU
Cochin), for lymphocyte collection; the surgeons (Profs. Y.
Chapuis and B. Dousset) and the medical and paramedical
staff at the Surgery and the Endocrine Departments of the
Hoˆpital Cochin, who managed the patients; Drs. A. Louvel
and F. Tissier, for the pathological examinations; and Dr. A.
Dugue and the staff of the Laudat Hormone Laboratory, for
hormone assays. We thank also Prof. C. Beldjord, Dr. B. Violet
(Institut Cochin), Drs. Papageorgiou and Sandrini (both at
NICHD, NIH), and other members of our laboratories for
helpful discussions. We thank Profs. J. C. Piette and M. Abid
and Drs. Z. Amoura and N. Chabbert-Buffet for referring their
patients for endocrine or genetic investigations. This work was
supported in part by the Plan Hospitalier de Recherche Cli-
nique (grant AOM 95201 to the COMETE Network, coor-
dinated by Prof. P. F. Plouin and dedicated to the study of
adrenal tumors) and the Association pour la Recherche sur le
Cancer (grant ARC 4225). L.G. was the recipient of a fellow-
ship from the Association pour la Recherche sur le Cancer.
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
Genome Database, http://gdbwww.gdb.org/ (for sequence
information)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/omim/ (for CNC [MIM 160980])
Whitehead Institute/MIT, Center for Genome Research,
http://www.genome.wi.mit.edu/ (for sequence information)
References
Bertherat J, Chanson P, Montminy M (1995) The cyclic aden-
osine 3′,5′-monophosphate-responsive factor CREB is con-
stitutively activated in human somatotroph adenomas. Mol
Endocrinol 9:777–783
Carney JA (1990) Psammomatous melanotic schwannoma: a
distinctive, heritable tumor with special associations, in-
cluding cardiac myxoma and the Cushing syndrome. Am J
Surg Pathol 14:206–222
Carney JA, Boccon-Gibod L, Jarka DE, Tanaka Y, Swee RG,
Unni KK, Stratakis CA (2001) Osteochondromyxoma of
bone: a congenital tumor associated with lentigines and
other unusual disorders. Am J Surg Pathol 25:164–176
Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL
(1985) The complex of myxomas, spotty pigmentation, and
endocrine overactivity. Medicine 64:270–283
Carney JA, Hruska LS, Beauchamp GD, Gordon H (1986)
Dominant inheritance of the complex of myxomas, spotty
pigmentation, and endocrine overactivity. Mayo Clin Proc
61:165–172
1442 Am. J. Hum. Genet. 71:1433–1442, 2002
Carney JA, Stratakis CA (1996) Ductal adenoma of the breast
and the Carney complex. Am J Surg Pathol 20:1154–1155
Carney JA, Stratakis CA (1998) Epithelioid blue nevus and
psammomatous melanotic schwannoma: the unusual pig-
mented skin tumors of the Carney complex. Semin Diagn
Pathol 15:216–224
Carney JA, Toorkey BC (1991) Ductal adenoma of the breast
with tubular features: a probable component of the complex
of myxomas, spotty pigmentation, endocrine overactivity,
and schwannomas. Am J Surg Pathol 15:722–731
Casey M, Mah C, Merliss AD, Kirschner LS, Taymans SE,
Denio AE, Korf B, Irvine AD, Hughes A, Carney JA, Stra-
takis CA, Basson CT (1998) Identification of a novel genetic
locus for familial cardiac myxomas and Carney complex.
Circulation 98:2560–2566
Casey M, Vaughan CJ, He J, Hatcher CJ, Winter JM, Were-
mowicz S, Montgomery K, Kucherlapati R, Morton CC,
Basson CT (2000) Mutations in the protein kinase A R1a
regulatory subunit cause familial cardiac myxomas and Car-
ney complex. J Clin Invest 106:R31–R38
Dahle MK, Knutsen HK, Tasken KA, Pilz R, Tasken K (2001)
Cyclic AMP regulates expression of the RIa subunit of
cAMP-dependent protein kinase through an alternatively
spliced 5′ UTR. Eur J Biochem 268:5920–5929
Gonzalez GA, Montminy MR (1989) Cyclic AMP stimulates
somatostatin gene transcription by phosphorylation of
CREB at serine 133. Cell 59:675–680
Groussin L, Jullian E, Perlemoine K, Leheup B, Luton JP, Ber-
tagna X, Bertherat J (2002) Mutations of the PRKAR1A
gene in Cushing’s syndrome due to sporadic primary pig-
mented nodular adrenocortical disease (PPNAD). J Clin En-
docrinol Metab 87:4324–4329
Groussin L, Massias J, Bertagna X, Bertherat J (2000) Loss of
expression of the ubiquitous transcription factor cAMP re-
sponse element-binding protein (CREB) and compensatory
overexpression of the activator CREMt in the human ad-
renocortical cancer cell line H295R. J Clin Endocrinol Me-
tab 85:345–354
Huang LJ, Taylor SS (1998) Dissecting cAMP binding domain
A in the RIa subunit of cAMP-dependent protein kinase:
distinct subsites for recognition of cAMP and the catalytic
subunit. J Biol Chem 273:26739–26746
Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C,
Cho YS, Cho-Chung YS, Stratakis CA (2000a) Mutations
of the gene encoding the protein kinase A type I-a regulatory
subunit in patients with the Carney complex. Nat Genet 26:
89–92
Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis
CA (2000b) Genetic heterogeneity and spectrum of muta-
tions of the PRKAR1A gene in patients with the Carney
complex. Hum Mol Genet 9:3037–3046
Kozak M (1997) Recognition of AUG and alternative initiator
codons is augmented by G in position4 but is not generally
affected by the nucleotides in positions 5 and 6. Embo
J 16:2482–2492
Kozak M (1999) Initiation of translation in prokaryotes and
eukaryotes. Gene 234:187–208
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters
A (1998) Severe early-onset obesity, adrenal insufficiency
and red hair pigmentation caused by POMC mutations in
humans. Nat Genet 19:155–157
Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N,
Hogg D (1999) Mutation of the CDKN2A 5′ UTR creates
an aberrant initiation codon and predisposes to melanoma.
Nat Genet 21:128–132
McKnight GS, Clegg CH, Uhler MD, Chrivia JC, Cadd GG,
Correll LA, Otten AD (1988) Analysis of the cAMP-depen-
dent protein kinase system using molecular genetic ap-
proaches. Recent Prog Horm Res 44:307–335
Ogreid D, Taylor SS (1990) Expression and characterization
of a truncated form of regulatory subunit of cAMP-depen-
dent protein kinase I lacking binding domain A. Adv Second
Messenger Phosphoprotein Res 24:196–201
Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis
CA (2000) Genetic and histologic studies of somatomam-
motropic pituitary tumors in patients with the “complex of
spotty skin pigmentation, myxomas, endocrine overactivity
and schwannomas” (Carney complex). J Clin Endocrinol
Metab 85:3860–3865
Premkumar A, Stratakis CA, Shawker TH, Papanicolaou DA,
Chrousos GP (1997) Testicular ultrasound in Carney com-
plex: report of three cases. J Clin Ultrasound 25:211–214
Raff SB, Carney JA, Krugman D, Doppman JL, Stratakis CA
(2000) Prolactin secretion abnormalities in patients with the
“syndrome of spotty skin pigmentation, myxomas, endo-
crine overactivity and schwannomas” (Carney complex). J
Pediatr Endocrinol Metab 13:373–379
Sandrini F, Matyakhina L, Bourdeau I, Farmakidis C, Keil M,
Kirschner LS, Stratakis CA (2002) PRKAR1A, a regulator
of protein kinase A, is mutated in children with Carney
complex and isolated micronodular adrenal hyperplasia.
Abstract presented at the Society for Pediatric Research
(SPR) Annual Meeting, Baltimore, May 6
Stratakis CA, Carney JA, Lin JP, Papanicolaou DA, Karl M,
Kastner DL, Pras E, Chrousos GP (1996) Carney complex,
a familial multiple neoplasia and lentiginosis syndrome:
analysis of 11 kindreds and linkage to the short arm of
chromosome 2. J Clin Invest 97:699–705
Stratakis CA, Courcoutsakis NA, Abati A, Filie A, Doppman
JL, Carney JA, Shawker T (1997) Thyroid gland abnor-
malities in patients with the syndrome of spotty skin pig-
mentation, myxomas, endocrine overactivity, and schwan-
nomas (Carney complex). J Clin Endocrinol Metab 82:
2037–2043
Stratakis CA, Kirschner LS, Carney JA (2001) Clinical and
molecular features of the Carney complex: diagnostic cri-
teria and recommendations for patient evaluation. J Clin
Endocrinol Metab 86:4041–4046
Stratakis CA, Papageorgiou T, Premkumar A, Pack S, Kir-
schner LS, Taymans SE, Zhuang Z, Oelkers WH, Carney
JA (2000) Ovarian lesions in Carney complex: clinical ge-
netics and possible predisposition to malignancy. J Clin En-
docrinol Metab 85:4359–4366
Stratakis CA, Sarlis N, Kirschner LS, Carney JA, Doppman
JL, Nieman LK, Chrousos GP, Papanicolaou DA (1999) Par-
adoxical response to dexamethasone in the diagnosis of pri-
mary pigmented nodular adrenocortical disease. Ann Intern
Med 131:585–591
